Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome
Active, not recruiting · NCT04496960 · Registry updated 2025-12-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome | Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, salivary gland disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-12-18 | NCT04496960 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Institute of Dental and Craniofacial Research (NIDCR) | 62 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National Institutes of Health Clinical Center | Bethesda | United States | 800 |